Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-4318 · 1 trial · 2 indications
Blood samples will be collected to determine the AUC0-inf of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the AUC0-24hrs of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the C12hrs of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the C24hrs of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the Cmax of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the Tmax of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the CL/F of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the Vz/F of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the t1/2 of MK-4318 in the presence of diltiazem.
| Arm | Type | Description |
|---|---|---|
| MK-4318 Plus Diltiazem | EXPERIMENTAL | Participants will move sequentially through 2 Periods. In Period 1, participants receive MK-4318 orally. In Period 2, participants receive MK-4318 orally plus diltiazem orally. |
| Name | Type | Description |
|---|---|---|
| MK-4318 | DRUG | Oral administration |
| Diltiazem | DRUG | Oral administration |
Inclusion Criteria The main inclusion criteria include but are not limited to the following: * Is in good health based on medical history and physical examination * Has a body mass index \>18 and ≤32 kg/m\^2, inclusive Exclusion Criteria The main exclusion criteria include but are not limited to...
MK-4318 is an investigational small molecule being developed by Merck & Company, Inc. (ticker MRK) for pain. It is in Phase 1 clinical development and has been studied in healthy volunteers. It is not an approved medicine.
MK-4318 is being developed for the treatment of pain. Its clinical testing so far has involved healthy adult volunteers rather than patients with a pain condition, so its use in pain is still under investigation and it is not approved for any indication.
MK-4318 is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor of the clinical program studying the compound.
MK-4318 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The compound remains investigational and has not been approved by the FDA for any use.
MK-4318 has been studied in one Phase 1 trial, NCT06692647, titled A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003). The trial enrolled 19 participants in the United States, included healthy volunteers, and is now completed.
The completed Phase 1 trial NCT06692647 enrolled 19 healthy adult volunteers of all sexes, aged 18 years and older, in the United States. It was an uncontrolled study without randomization or double blinding, and it evaluated MK-4318 together with diltiazem.